Annual CFO
-$16.96 M
+$4.94 M+22.56%
December 31, 2023
Summary
- As of February 12, 2025, RSLS annual cash flow from operations is -$16.96 million, with the most recent change of +$4.94 million (+22.56%) on December 31, 2023.
- During the last 3 years, RSLS annual CFO has fallen by -$8.41 million (-98.36%).
- RSLS annual CFO is now -98.36% below its all-time high of -$8.55 million, reached on December 31, 2020.
Performance
RSLS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$311.00 K
+$1.05 M+77.08%
September 30, 2024
Summary
- As of February 12, 2025, RSLS quarterly cash flow from operations is -$311.00 thousand, with the most recent change of +$1.05 million (+77.08%) on September 30, 2024.
- Over the past year, RSLS quarterly CFO has increased by +$2.47 million (+88.81%).
- RSLS quarterly CFO is now at all-time high.
Performance
RSLS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$6.20 M
+$2.47 M+28.49%
September 30, 2024
Summary
- As of February 12, 2025, RSLS TTM cash flow from operations is -$6.20 million, with the most recent change of +$2.47 million (+28.49%) on September 30, 2024.
- Over the past year, RSLS TTM CFO has increased by +$11.13 million (+64.25%).
- RSLS TTM CFO is now at all-time high.
Performance
RSLS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
RSLS Cash From Operations Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +22.6% | +88.8% | +64.3% |
3 y3 years | -98.4% | +96.0% | +54.8% |
5 y5 years | +38.3% | +68.1% | +23.6% |
RSLS Cash From Operations Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -10.3% | +22.6% | at high | +95.8% | at high | +75.2% |
5 y | 5-year | -98.4% | +22.6% | at high | +96.0% | at high | +75.2% |
alltime | all time | -98.4% | +49.6% | at high | +96.7% | at high | +81.6% |
ReShape Lifesciences Cash From Operations History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$311.00 K(-77.1%) | -$6.20 M(-28.5%) |
Jun 2024 | - | -$1.36 M(-34.5%) | -$8.67 M(-38.0%) |
Mar 2024 | - | -$2.07 M(-15.7%) | -$13.97 M(-17.6%) |
Dec 2023 | -$16.96 M(-22.6%) | -$2.46 M(-11.6%) | -$16.96 M(-2.1%) |
Sep 2023 | - | -$2.78 M(-58.3%) | -$17.33 M(-12.6%) |
Jun 2023 | - | -$6.66 M(+31.6%) | -$19.82 M(+1.2%) |
Mar 2023 | - | -$5.06 M(+78.9%) | -$19.59 M(-10.6%) |
Dec 2022 | -$21.90 M(+42.5%) | -$2.83 M(-46.3%) | -$21.90 M(-2.7%) |
Sep 2022 | - | -$5.27 M(-17.9%) | -$22.50 M(-10.1%) |
Jun 2022 | - | -$6.42 M(-13.0%) | -$25.03 M(+20.4%) |
Mar 2022 | - | -$7.38 M(+115.4%) | -$20.79 M(+35.2%) |
Dec 2021 | -$15.38 M(+79.8%) | -$3.43 M(-56.1%) | -$15.38 M(+12.1%) |
Sep 2021 | - | -$7.80 M(+256.5%) | -$13.71 M(+99.1%) |
Jun 2021 | - | -$2.19 M(+11.6%) | -$6.89 M(-5.2%) |
Mar 2021 | - | -$1.96 M(+11.3%) | -$7.27 M(-15.0%) |
Dec 2020 | -$8.55 M(-39.8%) | -$1.76 M(+80.5%) | -$8.55 M(+5.4%) |
Sep 2020 | - | -$976.00 K(-62.0%) | -$8.11 M(-28.9%) |
Jun 2020 | - | -$2.57 M(-20.9%) | -$11.41 M(-2.8%) |
Mar 2020 | - | -$3.25 M(+145.6%) | -$11.75 M(-17.3%) |
Dec 2019 | -$14.20 M(-48.3%) | -$1.32 M(-69.1%) | -$14.20 M(-28.9%) |
Sep 2019 | - | -$4.28 M(+47.6%) | -$19.97 M(-1.5%) |
Jun 2019 | - | -$2.90 M(-49.1%) | -$20.27 M(-15.1%) |
Mar 2019 | - | -$5.70 M(-19.6%) | -$23.87 M(-13.2%) |
Dec 2018 | -$27.49 M(+11.8%) | -$7.09 M(+54.9%) | -$27.49 M(-6.0%) |
Sep 2018 | - | -$4.58 M(-29.6%) | -$29.26 M(-3.5%) |
Jun 2018 | - | -$6.50 M(-30.2%) | -$30.33 M(+2.9%) |
Mar 2018 | - | -$9.32 M(+5.2%) | -$29.47 M(+19.8%) |
Dec 2017 | -$24.59 M(+19.0%) | -$8.86 M(+57.0%) | -$24.59 M(+27.7%) |
Sep 2017 | - | -$5.64 M(-0.1%) | -$19.26 M(+5.5%) |
Jun 2017 | - | -$5.65 M(+27.1%) | -$18.25 M(+0.3%) |
Mar 2017 | - | -$4.44 M(+25.7%) | -$18.20 M(-11.9%) |
Dec 2016 | -$20.66 M(-8.6%) | -$3.53 M(-23.7%) | -$20.66 M(-8.1%) |
Sep 2016 | - | -$4.63 M(-17.1%) | -$22.49 M(-5.9%) |
Jun 2016 | - | -$5.59 M(-19.0%) | -$23.89 M(+0.0%) |
Mar 2016 | - | -$6.90 M(+28.6%) | -$23.88 M(+5.7%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2015 | -$22.61 M(+16.6%) | -$5.36 M(-11.1%) | -$22.61 M(+4.3%) |
Sep 2015 | - | -$6.03 M(+8.0%) | -$21.67 M(+8.3%) |
Jun 2015 | - | -$5.59 M(-0.6%) | -$20.02 M(+3.2%) |
Mar 2015 | - | -$5.62 M(+26.9%) | -$19.40 M(+0.1%) |
Dec 2014 | -$19.38 M(+5.2%) | -$4.43 M(+1.1%) | -$19.38 M(+0.6%) |
Sep 2014 | - | -$4.38 M(-11.9%) | -$19.27 M(+2.6%) |
Jun 2014 | - | -$4.97 M(-11.2%) | -$18.78 M(-1.5%) |
Mar 2014 | - | -$5.60 M(+29.9%) | -$19.05 M(+3.4%) |
Dec 2013 | -$18.43 M(-18.0%) | -$4.31 M(+10.9%) | -$18.43 M(-6.0%) |
Sep 2013 | - | -$3.89 M(-26.0%) | -$19.60 M(-2.9%) |
Jun 2013 | - | -$5.25 M(+5.6%) | -$20.18 M(+0.5%) |
Mar 2013 | - | -$4.97 M(-9.3%) | -$20.08 M(-10.7%) |
Dec 2012 | -$22.48 M(+12.8%) | -$5.49 M(+22.6%) | -$22.48 M(+0.3%) |
Sep 2012 | - | -$4.47 M(-13.1%) | -$22.41 M(-3.1%) |
Jun 2012 | - | -$5.15 M(-30.2%) | -$23.12 M(+2.7%) |
Mar 2012 | - | -$7.37 M(+36.2%) | -$22.51 M(+12.9%) |
Dec 2011 | -$19.94 M(+45.9%) | -$5.41 M(+4.3%) | -$19.94 M(+10.4%) |
Sep 2011 | - | -$5.19 M(+14.5%) | -$18.06 M(+13.9%) |
Jun 2011 | - | -$4.53 M(-5.5%) | -$15.85 M(+6.9%) |
Mar 2011 | - | -$4.80 M(+35.7%) | -$14.83 M(+8.5%) |
Dec 2010 | -$13.66 M(-44.6%) | -$3.54 M(+18.6%) | -$13.66 M(-21.3%) |
Sep 2010 | - | -$2.98 M(-15.1%) | -$17.37 M(-14.7%) |
Jun 2010 | - | -$3.51 M(-3.4%) | -$20.35 M(-8.1%) |
Mar 2010 | - | -$3.63 M(-49.8%) | -$22.14 M(-10.2%) |
Dec 2009 | -$24.66 M(-26.8%) | -$7.24 M(+21.4%) | -$24.66 M(-8.4%) |
Sep 2009 | - | -$5.97 M(+12.7%) | -$26.93 M(-8.4%) |
Jun 2009 | - | -$5.30 M(-14.0%) | -$29.38 M(-8.6%) |
Mar 2009 | - | -$6.16 M(-35.3%) | -$32.15 M(-4.5%) |
Dec 2008 | -$33.67 M(+44.1%) | -$9.51 M(+12.9%) | -$33.67 M(+39.4%) |
Sep 2008 | - | -$8.42 M(+4.5%) | -$24.16 M(+53.5%) |
Jun 2008 | - | -$8.06 M(+5.0%) | -$15.74 M(+105.0%) |
Mar 2008 | - | -$7.68 M | -$7.68 M |
Dec 2007 | -$23.37 M(+44.0%) | - | - |
Dec 2006 | -$16.23 M(+57.9%) | - | - |
Dec 2005 | -$10.28 M | - | - |
FAQ
- What is ReShape Lifesciences annual cash flow from operations?
- What is the all time high annual CFO for ReShape Lifesciences?
- What is ReShape Lifesciences annual CFO year-on-year change?
- What is ReShape Lifesciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for ReShape Lifesciences?
- What is ReShape Lifesciences quarterly CFO year-on-year change?
- What is ReShape Lifesciences TTM cash flow from operations?
- What is the all time high TTM CFO for ReShape Lifesciences?
- What is ReShape Lifesciences TTM CFO year-on-year change?
What is ReShape Lifesciences annual cash flow from operations?
The current annual CFO of RSLS is -$16.96 M
What is the all time high annual CFO for ReShape Lifesciences?
ReShape Lifesciences all-time high annual cash flow from operations is -$8.55 M
What is ReShape Lifesciences annual CFO year-on-year change?
Over the past year, RSLS annual cash flow from operations has changed by +$4.94 M (+22.56%)
What is ReShape Lifesciences quarterly cash flow from operations?
The current quarterly CFO of RSLS is -$311.00 K
What is the all time high quarterly CFO for ReShape Lifesciences?
ReShape Lifesciences all-time high quarterly cash flow from operations is -$311.00 K
What is ReShape Lifesciences quarterly CFO year-on-year change?
Over the past year, RSLS quarterly cash flow from operations has changed by +$2.47 M (+88.81%)
What is ReShape Lifesciences TTM cash flow from operations?
The current TTM CFO of RSLS is -$6.20 M
What is the all time high TTM CFO for ReShape Lifesciences?
ReShape Lifesciences all-time high TTM cash flow from operations is -$6.20 M
What is ReShape Lifesciences TTM CFO year-on-year change?
Over the past year, RSLS TTM cash flow from operations has changed by +$11.13 M (+64.25%)